Skip to main content

Table 2 Multivariable association of IBM score, clinical factors with OS and PFS in the training and validation cohort (likelihood Ratio: Backward stepwise)

From: Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy

Variables

Training cohort

Validation cohort

HR (95% CI)

p

HR (95% CI)

p

Overall survival

 IBM score

8.636 (3.572–20.876)

< 0.001

4.479 (1.707–11.750)

0.068

 T stage*

0. 749 (0.423–1.325)

0.321

2.747 (1.403–5.376)

0.045

 M stage*

1.072 (0.259–4.448)

0.923

1.522 (0.120–19.340)

0.746

 Clinical stage*

1.345 (0.782–2.314)

0.284

0.679(0.283–1.632)

0.387

Progression-free survival

 IBM score

11.471 (3.123–42.134)

< 0.001

6.341 (1.667–24.115)

0.007

 Age

0.991 (0.332–1.035)

0.681

0.962 (0.902–1.026)

0.238

 Sex (female vs. male)

0.602 (0.283–1.280)

0.188

0.429 (0.123–1.499)

0.185

 M stage*

1.917 (0.929–3.960)

0.078

0.824 (0.237–2.862)

0.761

 Clinical stage*

1.006 (0.496–2.041)

0.986

1.484 (0.505–4.363)

0.473

  1. IBM, imaging biomarker; CI, confidence interval; HR, hazard ratio
  2. *According to American Joint Committee on Cancer (AJCC) staging system 6th